Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

Jefferies analyst Akash Tewari has maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and raised the price target from $870 to $930. This adjustment reflects a positive outlook on the company's performance.